Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.
Recruiting
Phase 4
Interventional Study
Infertility
Obesity
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 38
- Sex
- Female
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 62 (estimated)
- Sponsor
- Fundacion Dexeus · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a randomized, controlled clinical trial with a two-sided superiority hypothesis. The study evaluates whether a 12-week pre-treatment with semaglutide prior to ovarian stimulation improves the number of good-quality blastocysts in overweight and obese women undergoing in vitro fertilization (IVF), compared to no pre-treatment.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* ≤ 38 years
* AMH \>= 1 ng/mL or AFC \>= 6
* Body mass index (BMI) between 27 kg/m2 and 40 kg/m2
* Scheduled for IVF with freeze-all strategy
Exclusion Criteria:
* Severe male factor (sperm concentration \<5M/mL)
* Type 2 diabetes mellitus
* Prior use of GLP-1 Ras within the …
Contacts